Hendi Pharmaceutical Announcement: Shareholder Lei Xiaoyan will reduce 4,167,100 shares through centralized bidding from November 18, 2025, to February 17, 2026. The average reduction price is 14.25 yuan per share, accounting for 0.998% of the company’s total share capital. After the reduction, the shareholding will decrease to 11,492,900 shares, representing 2.752%, down from 15,660,000 shares, or 3.75%. The shares being reduced are all from shares issued before the company’s initial public offering. The reduction plan has expired and complies with relevant regulations.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Hendi Pharmaceuticals: Shareholder Lei Xiaoyan has reduced her holdings by 0.998%
Hendi Pharmaceutical Announcement: Shareholder Lei Xiaoyan will reduce 4,167,100 shares through centralized bidding from November 18, 2025, to February 17, 2026. The average reduction price is 14.25 yuan per share, accounting for 0.998% of the company’s total share capital. After the reduction, the shareholding will decrease to 11,492,900 shares, representing 2.752%, down from 15,660,000 shares, or 3.75%. The shares being reduced are all from shares issued before the company’s initial public offering. The reduction plan has expired and complies with relevant regulations.